Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?

Ann Oncol 2017; 28: 1207–1216 (doi: 10.1093/annonc/mdx081) In the original article, the acknowledgements section was incorrect. The following statement was missing: Dr. Rodon has been granted by Instituto de Salud Carlos III (ISCIII) with the project reference number PI15/00360, which has been selected as part of an operational program co-financed by the European Regional Development Fund (ERDF). This has now been corrected. Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?Annals of OncologyVol. 28Issue 6PreviewGastric cancer is the third leading cause of death from cancer worldwide. Systemic chemotherapy remains the mainstay therapeutic option for this poor prognosis cancer. Trastuzumab, the epidermal growth factor receptor 2 (ERBB2 or HER2)-antibody, is the only biological agent approved for the molecularly selected population of HER2-positive gastric cancer patients. Over the last decade, several groups have been working for deepening into the molecular characterization of gastric cancer, shedding some light into the heterogeneity of this tumour. Full-Text PDF Open Archive